Return to content in this issue

 

Omalizumab in the Treatment of Hyper-IgE Syndrome: 2 Case Reports

Gomes N1*, Miranda J2*, Lopes S1, Carneiro-Leão L2, Torres Costa J2, Baudrier T1, Azevedo F1

1Dermatovenereology Department, Centro Hospitalar Universitário de São João, Porto, Portugal
2Allergy and Clinical Immunology Department, Centro Hospitalar Universitário de São João, Porto, Portugal
*These authors are to be considered first authors.

J Investig Allergol Clin Immunol 2020; Vol 30(3) : 191-192
doi: 10.18176/jiaci.0469

Key words: DOCK8, Eczema, Hyper-IgE syndrome, Omalizumab, STAT3